STOCK TITAN

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Heron Therapeutics (HRTX) has appointed Michael Kaseta to its Board of Directors. Kaseta currently serves as CFO and COO of Liquidia and brings extensive experience in corporate finance, business strategy, and biopharma product commercialization. His previous roles include CFO positions at Aerami Therapeutics and Aralez Pharmaceuticals, as well as CFO at Sanofi North America, where he managed a $10 billion business across eight therapeutic areas. Kaseta holds a BBA in accounting from James Madison University and is a CPA.

Heron Therapeutics (HRTX) ha nominato Michael Kaseta nel suo Consiglio di Amministrazione. Kaseta attualmente ricopre il ruolo di CFO e COO di Liquidia e porta con sé un'ampia esperienza in finanza aziendale, strategia commerciale e commercializzazione di prodotti biopharma. Tra le sue esperienze precedenti, ha ricoperto posizioni di CFO presso Aerami Therapeutics e Aralez Pharmaceuticals, oltre ad essere stato CFO di Sanofi North America, dove ha gestito un'attività da 10 miliardi di dollari in otto aree terapeutiche. Kaseta ha conseguito una laurea in economia aziendale presso la James Madison University ed è un CPA.

Heron Therapeutics (HRTX) ha designado a Michael Kaseta como miembro de su Junta Directiva. Kaseta actualmente es CFO y COO de Liquidia y aporta una amplia experiencia en finanzas corporativas, estrategia empresarial y comercialización de productos biopharma. Sus roles anteriores incluyen posiciones de CFO en Aerami Therapeutics y Aralez Pharmaceuticals, así como CFO en Sanofi North America, donde gestionó un negocio de $10 mil millones en ocho áreas terapéuticas. Kaseta tiene una licenciatura en contabilidad de la James Madison University y es CPA.

헤론 테라퓨틱스 (HRTX)는 마이클 카세타를 이사회에 임명했습니다. 카세타는 현재 리퀴디아의 CFO이자 COO로 재직 중이며, 기업 금융, 비즈니스 전략 및 바이오제약 제품 상용화에 대한 광범위한 경험을 보유하고 있습니다. 그의 이전 역할에는 에라미 테라퓨틱스와 아랠레즈 제약에서의 CFO 직책이 포함되며, 샌오피 북미에서도 CFO로 재직하며 100억 달러 규모의 8개 치료 분야에서 사업을 관리했습니다. 카세타는 제임스 매디슨 대학교에서 회계학 학위를 받았고 공인회계사(CPA)입니다.

Heron Therapeutics (HRTX) a nommé Michael Kaseta au sein de son conseil d'administration. Kaseta est actuellement CFO et COO de Liquidia et possède une vaste expérience en finance d'entreprise, stratégie commerciale et commercialisation de produits biopharmaceutiques. Ses précédents rôles incluent des postes de CFO chez Aerami Therapeutics et Aralez Pharmaceuticals, ainsi que CFO chez Sanofi North America, où il a géré une entreprise de 10 milliards de dollars dans huit domaines thérapeutiques. Kaseta détient un BBA en comptabilité de l'Université James Madison et est un CPA.

Heron Therapeutics (HRTX) hat Michael Kaseta in seinen Verwaltungsrat berufen. Kaseta ist derzeit CFO und COO von Liquidia und bringt umfangreiche Erfahrung in Unternehmensfinanzen, Geschäftsstrategie und der Kommerzialisierung von Biopharma-Produkten mit. Zu seinen bisherigen Tätigkeiten gehören die CFO-Positionen bei Aerami Therapeutics und Aralez Pharmaceuticals sowie CFO bei Sanofi Nordamerika, wo er ein Geschäft mit einem Umfang von 10 Milliarden Dollar in acht therapeutischen Bereichen leitete. Kaseta hat einen BBA-Abschluss in Buchhaltung von der James Madison University und ist ein CPA.

Positive
  • Addition of experienced executive with significant financial and operational expertise in biotech sector
  • New director brings experience managing $10 billion business portfolio
  • Strategic addition of leadership with background in product commercialization and launches
Negative
  • None.

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.

Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Therapeutics, Inc., a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension. Previously, Mr. Kaseta served as the Chief Financial Officer at Aralez Pharmaceuticals, Inc., and spent eleven years at Sanofi S.A. in a variety of financial roles, culminating in the Chief Financial Officer role at Sanofi North America, Global Services. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Mr. Kaseta holds a BBA in accounting from James Madison University, is a CPA (inactive) licensed in the state of New Jersey, and serves as a director of Bryn Pharma.

"We are excited to welcome Mike and his deep experience in commercial biotechnology leadership to Heron's Board of Directors," said Craig Collard, Chief Executive Officer of Heron. "I look forward to working with Mike more closely and I am confident that he will be an important asset to the Board as we drive continued growth of our existing portfolio of proprietary products focused on improving the lives of patients."

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-appointment-of-michael-kaseta-to-board-of-directors-302295904.html

SOURCE Heron Therapeutics, Inc.

FAQ

Who is the newest board member appointed to Heron Therapeutics (HRTX)?

Michael Kaseta, who currently serves as CFO and COO of Liquidia , has been appointed to Heron Therapeutics' Board of Directors.

What is Michael Kaseta's current role outside of HRTX?

Michael Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia , a biopharmaceutical company developing therapies for rare cardiopulmonary diseases.

What was Michael Kaseta's role at Sanofi before joining HRTX's board?

At Sanofi, Kaseta served as CFO of Sanofi North America, Global Services, managing a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas.

Heron Therapeutics, Inc.

NASDAQ:HRTX

HRTX Rankings

HRTX Latest News

HRTX Stock Data

165.78M
150.99M
0.71%
81.59%
19%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO